The Filings Report

Vertex Pharmaceuticals Inc

VRTXNasdaqCIK 875320Healthcare / Drug Manufacturersfiscal year ends December70 quarters since 2009

Revenue, Q2 FY2026
$3.3B
+12.5% on Q2 FY2025
Net income
$1.1B
+6.5% on Q2 FY2025
Free cash flow
$1.0B
+9.3% on Q2 FY2025
Diluted EPS
$4.31
+8.0% on Q2 FY2025
Revenue, TTM
$12.6B
trailing four quarters
Net margin, TTM
35.0%
net income $4.4B
Free cash flow, TTM
$3.8B
$4.3B less $497M capex
Cash and equivalents
$6.1B
long-term debt —, Jun 30, 2026
Shares, 12-month change
−1.1%
253M shares, Jun 30, 2026
Buybacks, TTM
$2.0B
1.4% of market value
Dividends, TTM
—
no yield
Market value
$141.7B
at the close, buybacks

Latest quarter Q2 FY2026, filed August 4, 2026. Trailing figures sum the latest four quarters. Market values at the latest close, from a market data vendor.

In Q2 FY2026, the quarter ended June 30, 2026, Vertex Pharmaceuticals Inc reported revenue of $3.3B, +12.5% on Q2 FY2025, and net income of $1.1B (+6.5%). Operating margin was 37.4%. Free cash flow, operating cash flow less capital expenditures, was $1.0B ($1.1B less $112M). Diluted earnings per share were $4.31.

The last 16 quarters

Q3 FY2022 to Q2 FY2026, through the filing of August 4, 2026.

Revenue and net incomeRevenueNet income
−$4B−$2B$0$2B$4BQ3'22, Revenue: $2.3BQ3'22, Net income: $931MQ3'22Q4'22, Revenue: $2.3BQ4'22, Net income: $819MQ4'22Q1'23, Revenue: $2.4BQ1'23, Net income: $700MQ1'23Q2'23, Revenue: $2.5BQ2'23, Net income: $916MQ2'23Q3'23, Revenue: $2.5BQ3'23, Net income: $1.0BQ3'23Q4'23, Revenue: $2.5BQ4'23, Net income: $969MQ4'23Q1'24, Revenue: $2.7BQ1'24, Net income: $1.1BQ1'24Q2'24, Revenue: $2.6BQ2'24, Net income: −$3.6BQ2'24Q3'24, Revenue: $2.8BQ3'24, Net income: $1.0BQ3'24Q4'24, Revenue: $2.9BQ4'24, Net income: $913MQ4'24Q1'25, Revenue: $2.8BQ1'25, Net income: $646MQ1'25Q2'25, Revenue: $3.0BQ2'25, Net income: $1.0BQ2'25Q3'25, Revenue: $3.1BQ3'25, Net income: $1.1BQ3'25Q4'25, Revenue: $3.2BQ4'25, Net income: $1.2BQ4'25Q1'26, Revenue: $3.0BQ1'26, Net income: $1.0BQ1'26Q2'26, Revenue: $3.3BQ2'26, Net income: $1.1BQ2'26−$4B−$2B$0$2B$4BQ3'22, Revenue: $2.3BQ3'22, Net income: $931MQ4'22, Revenue: $2.3BQ4'22, Net income: $819MQ4'22Q1'23, Revenue: $2.4BQ1'23, Net income: $700MQ2'23, Revenue: $2.5BQ2'23, Net income: $916MQ2'23Q3'23, Revenue: $2.5BQ3'23, Net income: $1.0BQ4'23, Revenue: $2.5BQ4'23, Net income: $969MQ4'23Q1'24, Revenue: $2.7BQ1'24, Net income: $1.1BQ2'24, Revenue: $2.6BQ2'24, Net income: −$3.6BQ2'24Q3'24, Revenue: $2.8BQ3'24, Net income: $1.0BQ4'24, Revenue: $2.9BQ4'24, Net income: $913MQ4'24Q1'25, Revenue: $2.8BQ1'25, Net income: $646MQ2'25, Revenue: $3.0BQ2'25, Net income: $1.0BQ2'25Q3'25, Revenue: $3.1BQ3'25, Net income: $1.1BQ4'25, Revenue: $3.2BQ4'25, Net income: $1.2BQ4'25Q1'26, Revenue: $3.0BQ1'26, Net income: $1.0BQ2'26, Revenue: $3.3BQ2'26, Net income: $1.1BQ2'26

Net income losses drawn in red.

Free cash flow
−$4B−$2B$0$2BQ3'22, Free cash flow: $901MQ3'22Q4'22, Free cash flow: $1.0BQ4'22Q1'23, Free cash flow: $858MQ1'23Q2'23, Free cash flow: $1.1BQ2'23Q3'23, Free cash flow: $1.2BQ3'23Q4'23, Free cash flow: $177MQ4'23Q1'24, Free cash flow: $1.2BQ1'24Q2'24, Free cash flow: −$3.8BQ2'24Q3'24, Free cash flow: $1.3BQ3'24Q4'24, Free cash flow: $492MQ4'24Q1'25, Free cash flow: $778MQ1'25Q2'25, Free cash flow: $927MQ2'25Q3'25, Free cash flow: $1.1BQ3'25Q4'25, Free cash flow: $349MQ4'25Q1'26, Free cash flow: $1.3BQ1'26Q2'26, Free cash flow: $1.0BQ2'26−$4B−$2B$0$2BQ3'22, Free cash flow: $901MQ4'22, Free cash flow: $1.0BQ4'22Q1'23, Free cash flow: $858MQ2'23, Free cash flow: $1.1BQ2'23Q3'23, Free cash flow: $1.2BQ4'23, Free cash flow: $177MQ4'23Q1'24, Free cash flow: $1.2BQ2'24, Free cash flow: −$3.8BQ2'24Q3'24, Free cash flow: $1.3BQ4'24, Free cash flow: $492MQ4'24Q1'25, Free cash flow: $778MQ2'25, Free cash flow: $927MQ2'25Q3'25, Free cash flow: $1.1BQ4'25, Free cash flow: $349MQ4'25Q1'26, Free cash flow: $1.3BQ2'26, Free cash flow: $1.0BQ2'26

Operating cash flow less capital expenditures; negative quarters in red.

Cash and equivalents against long-term debtCash and equivalentsLong-term debt
$0$5B$10B$15BQ3'22, Cash and equivalents: $9.2BQ3'22Q4'22, Cash and equivalents: $10.5BQ4'22Q1'23, Cash and equivalents: $9.3BQ1'23Q2'23, Cash and equivalents: $10.2BQ2'23Q3'23, Cash and equivalents: $11.1BQ3'23Q4'23, Cash and equivalents: $10.4BQ4'23Q1'24, Cash and equivalents: $9.2BQ1'24Q2'24, Cash and equivalents: $4.6BQ2'24Q3'24, Cash and equivalents: $5.2BQ3'24Q4'24, Cash and equivalents: $4.6BQ4'24Q1'25, Cash and equivalents: $4.7BQ1'25Q2'25, Cash and equivalents: $5.0BQ2'25Q3'25, Cash and equivalents: $4.9BQ3'25Q4'25, Cash and equivalents: $5.1BQ4'25Q1'26, Cash and equivalents: $5.5BQ1'26Q2'26, Cash and equivalents: $6.1BQ2'26$0$5B$10B$15BQ3'22, Cash and equivalents: $9.2BQ4'22, Cash and equivalents: $10.5BQ4'22Q1'23, Cash and equivalents: $9.3BQ2'23, Cash and equivalents: $10.2BQ2'23Q3'23, Cash and equivalents: $11.1BQ4'23, Cash and equivalents: $10.4BQ4'23Q1'24, Cash and equivalents: $9.2BQ2'24, Cash and equivalents: $4.6BQ2'24Q3'24, Cash and equivalents: $5.2BQ4'24, Cash and equivalents: $4.6BQ4'24Q1'25, Cash and equivalents: $4.7BQ2'25, Cash and equivalents: $5.0BQ2'25Q3'25, Cash and equivalents: $4.9BQ4'25, Cash and equivalents: $5.1BQ4'25Q1'26, Cash and equivalents: $5.5BQ2'26, Cash and equivalents: $6.1BQ2'26

Positions at each quarter end, as filed; short-term investments are not included.

Income statement

Last eight quarters, newest first, through Q2 FY2026 filed August 4, 2026.

Vertex Pharmaceuticals Inc income statement, quarterly
Millions of dollarsQ2 FY2026ended Jun 30, 2026filed Aug 4, 2026Q1 FY2026ended Mar 31, 2026filed May 5, 2026Q4 FY2025ended Dec 31, 2025filed Feb 13, 2026Q3 FY2025ended Sep 30, 2025filed Nov 4, 2025Q2 FY2025ended Jun 30, 2025filed Aug 5, 2025Q1 FY2025ended Mar 31, 2025filed May 6, 2025Q4 FY2024ended Dec 31, 2024filed Feb 13, 2025Q3 FY2024ended Sep 30, 2024filed Nov 5, 2024YoYQ2 FY2026vs Q2 FY2025
Revenue3,3342,9873,1903,0762,9652,7702,9122,772+12.5%
Cost of revenue489393466415408363423393+20.0%
Gross profit—————————
Research and development—————————
Selling, general and administrative582494487445425396378372+37.1%
Operating income1,2471,1381,2061,1861,1516301,0261,116+8.3%
Other income (expense)2407(10)13(18)(15)(17)+84.1%
Pretax income1,3921,2531,3311,2991,2837301,1371,224+8.5%
Income tax29222214021625084224179+16.8%
Net income1,1001,0311,1911,0831,0336469131,045+6.5%
Diluted EPS ($)4.314.02—4.203.992.49—4.01+8.0%
Diluted shares (millions)255256—258259260—261—

Fourth quarters are the fiscal year less the first nine months when the filer reports no discrete fourth quarter, and are marked. Diluted EPS is never derived, so a derived quarter shows none. Italic figures are derived.

Balance sheet

Last eight quarters, newest first, through Q2 FY2026 filed August 4, 2026.

Vertex Pharmaceuticals Inc balance sheet, quarterly
Millions of dollarsQ2 FY2026ended Jun 30, 2026filed Aug 4, 2026Q1 FY2026ended Mar 31, 2026filed May 5, 2026Q4 FY2025ended Dec 31, 2025filed Feb 13, 2026Q3 FY2025ended Sep 30, 2025filed Nov 4, 2025Q2 FY2025ended Jun 30, 2025filed Aug 5, 2025Q1 FY2025ended Mar 31, 2025filed May 6, 2025Q4 FY2024ended Dec 31, 2024filed Feb 13, 2025Q3 FY2024ended Sep 30, 2024filed Nov 5, 2024YoYQ2 FY2026vs Q2 FY2025
Cash and equivalents6,1445,4935,0854,9404,9724,6754,5705,239+23.6%
Short-term investments1,7091,7541,5231,3471,4111,5271,5461,285+21.1%
Total current assets12,54411,73011,20110,57010,42810,0099,5969,804+20.3%
Total assets27,42326,48425,64324,86224,03722,88122,53322,240+14.1%
Total current liabilities3,9383,8813,8614,4754,1383,7833,5653,973−4.8%
Long-term debt—————————
Total liabilities7,1757,1236,9777,5446,8616,3846,1246,609+4.6%
Stockholders’ equity20,24819,36218,66617,31917,17516,49616,41015,631+17.9%
Shares outstanding (millions)253254254254256257257258—

Positions at each period end. Nothing on this statement is derived. Long-term debt is the filed noncurrent line only; no total-debt composite is constructed across filers. Italic figures are derived.

Cash flow statement

Last eight quarters, newest first, through Q2 FY2026 filed August 4, 2026.

Vertex Pharmaceuticals Inc cash flow statement, quarterly
Millions of dollarsQ2 FY2026ended Jun 30, 2026filed Aug 4, 2026Q1 FY2026ended Mar 31, 2026filed May 5, 2026Q4 FY2025ended Dec 31, 2025filed Feb 13, 2026Q3 FY2025ended Sep 30, 2025filed Nov 4, 2025Q2 FY2025ended Jun 30, 2025filed Aug 5, 2025Q1 FY2025ended Mar 31, 2025filed May 6, 2025Q4 FY2024ended Dec 31, 2024filed Feb 13, 2025Q3 FY2024ended Sep 30, 2024filed Nov 5, 2024YoYQ2 FY2026vs Q2 FY2025
Operating cash flow1,1251,4284981,2411,0738195851,370+4.9%
Capital expenditures112133149102146419368−23.0%
Free cash flow (CFO − capex)1,0131,2953491,1409277784921,302+9.3%
Depreciation and amortization5756565452484753+9.3%
Share repurchases4703371281,071392426418308+19.8%
Dividends paid—————————

10-Qs file cash flows as year-to-date totals, so quarterly figures are differenced from consecutive filings and marked. Free cash flow is operating cash flow less capital expenditures, computed from the two filed lines. Italic figures are derived.

Annual statements

Every fiscal year filed, newest first, through FY2025 filed February 13, 2026.

Income statement

Vertex Pharmaceuticals Inc income statement, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 13, 2026FY2024ended Dec 31, 2024filed Feb 13, 2025FY2023ended Dec 31, 2023filed Feb 15, 2024FY2022ended Dec 31, 2022filed Feb 10, 2023FY2021ended Dec 31, 2021filed Feb 9, 2022FY2020ended Dec 31, 2020filed Feb 11, 2021FY2019ended Dec 31, 2019filed Feb 13, 2020FY2018ended Dec 31, 2018filed Feb 13, 2019FY2017ended Dec 31, 2017filed Feb 15, 2018FY2016ended Dec 31, 2016filed Feb 23, 2017FY2015ended Dec 31, 2015filed Feb 16, 2016FY2014ended Dec 31, 2014filed Feb 13, 2015FY2013ended Dec 31, 2013filed Feb 11, 2014FY2012ended Dec 31, 2012filed Mar 1, 2013FY2011ended Dec 31, 2011filed Feb 22, 2012FY2010ended Dec 31, 2010filed Feb 17, 2011FY2009ended Dec 31, 2009filed May 3, 2010FY2008ended Dec 31, 2008filed May 3, 2010
Revenue12,00111,0209,8698,9317,5746,2064,1633,0482,4891,7021,0325801,2121,5271,411143102176
Cost of revenue1,6511,5311,2621,080904736548410275210————————
Gross profit——————————————————
Research and development————3,0511,8301,7551,4161,3251,048996856882766708637550517
Selling, general and administrative1,7531,4641,137945840771659558496433377305356433401188130101
Operating income4,173(233)3,8324,3072,7822,8561,19863512310(467)(692)(610)47114(696)(614)(463)
Other income (expense)(8)(86)(23)(165)5297192(1)(81)4(7)3070(16)———
Pretax income4,6432494,3804,2322,7303,1171,395600(16)(67)(558)(735)(626)3260(755)(642)(460)
Income tax690784760910388405218(1,487)(107)17307(122)0190——
Net income3,953(536)3,6203,3222,3422,7121,1772,097263(112)(556)(739)(445)(107)30(755)(642)—
Diluted EPS ($)15.32(2.08)13.8912.829.0110.294.518.091.04(0.46)(2.31)(3.14)(1.98)(0.50)0.14(3.77)(3.71)(3.27)
Diluted shares (millions)258258261259260263261259253245241235225215209200173141

Balance sheet

Vertex Pharmaceuticals Inc balance sheet, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 13, 2026FY2024ended Dec 31, 2024filed Feb 13, 2025FY2023ended Dec 31, 2023filed Feb 15, 2024FY2022ended Dec 31, 2022filed Feb 10, 2023FY2021ended Dec 31, 2021filed Feb 9, 2022FY2020ended Dec 31, 2020filed Feb 11, 2021FY2019ended Dec 31, 2019filed Feb 13, 2020FY2018ended Dec 31, 2018filed Feb 13, 2019FY2017ended Dec 31, 2017filed Feb 15, 2018FY2016ended Dec 31, 2016filed Feb 23, 2017FY2015ended Dec 31, 2015filed Feb 16, 2016FY2014ended Dec 31, 2014filed Feb 13, 2015FY2013ended Dec 31, 2013filed Feb 11, 2014FY2012ended Dec 31, 2012filed Mar 1, 2013FY2011ended Dec 31, 2011filed Feb 22, 2012FY2010ended Dec 31, 2010filed Feb 17, 2011FY2009ended Dec 31, 2009filed May 3, 2010FY2008ended Dec 31, 2008filed May 3, 2010
Cash and equivalents5,0854,57010,36910,5046,7955,9883,1092,6501,6651,184715625569489475243447389
Short-term investments1,5231,546849275730671699518423—————————
Total current assets11,2019,59614,14413,2359,5618,1334,8233,8432,6491,8321,4071,5471,5891,5901,3311,0571,307—
Total assets25,64322,53322,73018,15113,43311,7528,3186,2623,5592,8972,4992,3352,3192,7592,2041,7251,955—
Total current liabilities3,8613,5653,5472,7422,1421,8781,3351,120807793506368398433392475285—
Long-term debt——————————————————
Total liabilities6,9776,1245,1504,2383,3333,0652,2331,8111,5041,5591,4051,2389631,5251,2391,221859—
Stockholders’ equity18,66616,41017,58013,91310,1008,6876,0854,4352,0291,1579401,0751,356999787504——
Shares outstanding (millions)254257258257255260259256254248246242236218210204202—

Cash flow statement

Vertex Pharmaceuticals Inc cash flow statement, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 13, 2026FY2024ended Dec 31, 2024filed Feb 13, 2025FY2023ended Dec 31, 2023filed Feb 15, 2024FY2022ended Dec 31, 2022filed Feb 10, 2023FY2021ended Dec 31, 2021filed Feb 9, 2022FY2020ended Dec 31, 2020filed Feb 11, 2021FY2019ended Dec 31, 2019filed Feb 13, 2020FY2018ended Dec 31, 2018filed Feb 13, 2019FY2017ended Dec 31, 2017filed Feb 15, 2018FY2016ended Dec 31, 2016filed Feb 23, 2017FY2015ended Dec 31, 2015filed Feb 16, 2016FY2014ended Dec 31, 2014filed Feb 13, 2015FY2013ended Dec 31, 2013filed Feb 11, 2014FY2012ended Dec 31, 2012filed Mar 1, 2013FY2011ended Dec 31, 2011filed Feb 22, 2012FY2010ended Dec 31, 2010filed Feb 17, 2011FY2009ended Dec 31, 2009filed May 3, 2010FY2008ended Dec 31, 2008filed May 3, 2010
Operating cash flow3,631(493)3,5374,1302,6443,2541,5691,270845236(365)(573)(61)268144(635)(428)(226)
Capital expenditures438298200205235260759599574551517135382332
Free cash flow (CFO − capex)3,194(790)3,3373,9252,4092,9941,4941,175746180(411)(624)(112)197109(673)(451)(259)
Depreciation and amortization2102071811481261101077261616263483835303032
Share repurchases2,0171,17742801,42553918635000————————
Dividends paid——————————————————

Insider activity

Form 4 filings by officers, directors and 10% owners, November 1, 2024 to November 1, 2026. Only open-market purchases and sales count as buys and sells; awards, exercises, tax withholding and gifts are listed in grey and never counted.

Bought, three months
$0
0 purchases by 0 insiders; officers and directors $0
Sold, three months
$0
0 sales by 0 insiders; officers and directors $0
Bought, twelve months
$0
0 purchases by 0 insiders; officers and directors $0
Sold, twelve months
$158M
93 sales by 13 insiders; officers and directors $158M

The last 25 transactions

TradedInsiderRoleTransactionSharesPriceValueHeld afterFiled
Oct 20, 2026Brennan Daniel J.Directoraward795$503.47$400K795Oct 22, 2026
Sep 8, 2026van Grunsven JasperEVP, CP and NPPOaward8,682$0.00—8,682Sep 10, 2026
Aug 28, 2026Ambrose KristenSVP & Chief Accounting Officeraward5,000$0.00—11,624Sep 1, 2026
Aug 27, 2026Sachs Bruce IDirectorgift6,000$0.00—39,000Aug 31, 2026
Jul 21, 2026Tatsis OuraniaEVP, Chief Reg. & Quality Off.award8,251$0.00—53,572Jul 23, 2026
Jul 21, 2026Sachdev AmitEVP Chief Patient & Ext Af Offaward8,251$0.00—66,512Jul 23, 2026
Jul 2, 2026Tatsis OuraniaEVP, Chief Reg. & Quality Off.open-market sale10b5-11,500$524.99$787K45,321Jul 7, 2026
Jul 2, 2026McKechnie DuncanEVP, Chief Commercial Officeropen-market sale10b5-11,541$519.00$800K11,001Jul 7, 2026
Jul 1, 2026Liu JoyEVP and Chief Legal Officeropen-market sale10b5-1828$502.71$416K19,131Jul 6, 2026
Jun 26, 2026Bozic CarmenEVP and CMOopen-market sale10b5-1596$482.50$288K15,337Jun 30, 2026
Jun 18, 2026Bozic CarmenEVP and CMOopen-market sale10b5-11,020$462.17$471K15,933Jun 23, 2026
Jun 15, 2026Bozic CarmenEVP and CMOopen-market sale10b5-14,062$450.00$2M16,953Jun 17, 2026
Jun 5, 2026Bozic CarmenEVP and CMOopen-market sale10b5-11,745$450.00$785K21,015Jun 9, 2026
Jun 1, 2026Liu JoyEVP and Chief Legal Officeropen-market sale10b5-1828$439.91$364K19,959Jun 3, 2026
May 29, 2026Bozic CarmenEVP and CMOopen-market sale10b5-11,974$450.00$888K22,760Jun 2, 2026
May 15, 2026Bunnage Mark E.EVP, Chief Scientific Officeropen-market sale10b5-133$453.45$15K7,284May 19, 2026
May 15, 2026Bozic CarmenEVP and CMOopen-market sale10b5-11,354$453.45$614K24,734May 19, 2026
May 12, 2026Bozic CarmenEVP and CMOopen-market sale10b5-16,988$450.00$3M26,088May 14, 2026
May 4, 2026Bhatia Sangeeta N.Directoropen-market sale10b5-1318$423.73$135K4,924May 5, 2026
May 1, 2026Upadhyay SuketuDirectordisposition to issuer796——1,558May 5, 2026
May 1, 2026Thornberry NancyDirectoraward472$0.00—2,507May 5, 2026
May 1, 2026Thornberry NancyDirectordisposition to issuer398——2,109May 5, 2026
May 1, 2026Schneider JenniferDirectoraward472$0.00—2,190May 5, 2026
May 1, 2026Schneider JenniferDirectordisposition to issuer796——1,394May 5, 2026
May 1, 2026Mckenzie DianaDirectoraward943$0.00—3,174May 5, 2026

Full insider history for Vertex Pharmaceuticals Inc, or insider activity across all companies. A record of filings, not a recommendation.

Tracked funds holding it

1 of the tracked managers held VRTX in their latest 13F filing, through August 14, 2026. Weight is the share of the fund’s reported portfolio. How the funds have traded VRTX by quarter.

FundManagerQuarterValueSharesWeightMove
Baron Capital GroupRon BaronQ2 2026$3M6,0000.00%trimmed −20.0%

Sources

Fiscal year ends in month 12; periods are labeled with the issuer's own fiscal calendar. Values are as most recently filed (restatements apply; per-share values are on current split basis per the connector's split table, flagged in adjusted). Flow items flagged in `derived` were computed (Q4 = FY − nine months; quarterly cash flow differenced from year-to-date filings) rather than read from a filing. `reconciliation.repaired` lists periods where a full-year figure was filed in a quarter slot: that row was dropped and the quarter rebuilt from the annual figure. `reconciliation.quarantined` lists periods where four filed quarters do not sum to the filed year — those quarterly values are withheld, so a blank there is a withholding rather than an absence of reporting.

Filer
VERTEX PHARMACEUTICALS INC / MA, CIK 875320 on EDGAR
Extract generated
August 27, 2026
Withheld
4 line-years whose four quarters do not sum to the filed year: income tax FY2012, operating income FY2012, pretax income FY2012, rnd FY2012
Repaired
none
XBRL concepts behind each line

Income statement

Revenue: RevenueFromContractWithCustomerExcludingAssessedTax, Revenues
Cost of revenue: CostOfGoodsAndServicesSold
Gross profit: not filed
Research and development: ResearchAndDevelopmentExpense
Selling, general and administrative: SellingGeneralAndAdministrativeExpense
Operating income: OperatingIncomeLoss
Other income (expense): OtherNonoperatingIncomeExpense
Pretax income: IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest, IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
Income tax: IncomeTaxExpenseBenefit
Net income: NetIncomeLoss
Diluted EPS ($): EarningsPerShareDiluted
Diluted shares (millions): WeightedAverageNumberOfDilutedSharesOutstanding

Balance sheet

Cash and equivalents: CashAndCashEquivalentsAtCarryingValue
Short-term investments: MarketableSecuritiesCurrent
Total current assets: AssetsCurrent
Total assets: Assets
Total current liabilities: LiabilitiesCurrent
Long-term debt: LongTermDebt
Total liabilities: Liabilities
Stockholders’ equity: StockholdersEquity
Shares outstanding (millions): dei:EntityCommonStockSharesOutstanding

Cash flow statement

Operating cash flow: NetCashProvidedByUsedInOperatingActivities
Capital expenditures: PaymentsToAcquirePropertyPlantAndEquipment
Free cash flow (CFO − capex): not filed
Depreciation and amortization: DepreciationDepletionAndAmortization
Share repurchases: PaymentsForRepurchaseOfCommonStock
Dividends paid: not filed

The data

The statements on this page as files, generated August 27, 2026.

JSON file
/data/financials/VRTX.json